(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Netflix’s Price Hikes Just Got Rejected by an Italian Court. Here’s Why It Matters Everywhere - 2Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'
- 3Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- 4Manual for 6 well known Amusement Park
- 5South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Cocoa Prices Sink on Favorable Crop Conditions in West Africa
- Iran-backed Iraqi militias attack Kurdistan over 450 times since beginning of war
- Qantas and Virgin Australia Ban Power Bank Usage on Flights Following Safety Incidents
- Malaysian broadcaster rejects altered graphic about electricity rate hike
- Cases of norovirus are on the rise just in time for the holiday season
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Top 10 Arising Advances That Will Shape What's in store
- Remarkable Spots for Hot Air Swelling All over The Planet
